The startup provides neuroprotective therapy utilizing neurodegeneration techniques to treat neurological diseases such as Amyotrophic Lateral Sclerosis, Parkinson's, Alzheimer's, and Multiple Sclerosis. This therapy aims to slow disease progression and improve patient quality of life by targeting the underlying mechanisms of neurodegeneration.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for neurodegenerative diseases like Amyotrophic Lateral Sclerosis, Parkinson's, Alzheimer's, and Multiple Sclerosis primarily focus on symptom management, with no available therapies that effectively prevent disease progression by protecting neurons from degeneration. Identifying naturally occurring neuroprotective antibodies in patients is challenging due to the vast diversity of antibodies generated by the human immune system. Existing therapeutic strategies often rely on immunosuppression, which carries the risk of compromising patients’ immune systems.
Solution
GenrAb is developing neuroprotective therapies by harnessing the power of the human immune system to identify and develop fully human monoclonal antibodies (mAbs) that can slow or halt the progression of neurological disorders. The company's proprietary Antibody Gene Signature (AGS) technology identifies and clones rare, therapeutically beneficial mAbs from patients experiencing neurodegeneration. These mAbs are designed to protect neurons without immunosuppression, offering a novel approach to treating neurodegenerative diseases. GenrAb's lead mAb, TGM-010, has demonstrated a reduction in disability in preclinical models and shows promise in treating multiple neurologic disorders by targeting a conserved neurodegenerative pathway.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as ALS, Parkinson’s, Alzheimer’s, and Multiple Sclerosis, as well as the clinicians and researchers focused on developing novel neuroprotective therapies.
Features
- Proprietary Antibody Gene Signature (AGS) technology for identifying neuroprotective mAbs
- Fully human mAbs with high affinity for central nervous system (CNS) tissue and cells
- TGM-010, a lead mAb with a US patent issued for its composition and fragments
- Demonstrated neuroprotective capabilities in vitro and in preclinical models of neurologic disease
- AGS technology identifies disease-associated antibody somatic hypermutations
- mAbs are cloned and screened in vitro for neuroprotection and lack of neurotoxicity
- Identification of a unique target for TGM-010 involved in managing neuronal survival
- Growing pipeline of fully human mAbs with high CNS tissue and cell-binding affinity